Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity
Novel 3D Hematological Malignancy Organoid Platform to Study Disease Biology and Perform Chemosensitivity Assays for Patient-Specific Care
Wake Forest University Health Sciences
70 participants
May 16, 2019
OBSERVATIONAL
Conditions
Summary
The objective of this project is to compare chemosensitivity between chemotherapy combinations in bone marrow aspirates using 3D organoid models. The investigators overarching hypothesis is that 3D organoids are ideal to test chemosensitivity in real time, to provide personalized medicine and guidance in the setting of relapsed hematologic malignancy and potentially other cancers.
Eligibility
Inclusion Criteria2
- Patients with suspected or confirmed hematologic malignancy undergoing a bone marrow biopsy as part of their care.
- The ability to understand and willingness to sign an IRB approved informed consent document.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Bone marrow aspirates will be collected from participants with hematologic malignancy being evaluated for relapsed disease to create three-dimensional constructs using a three-dimensional bioprinting methodology for automated organoid biofabrication.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03890614